A Challenging Case of IgAN and Vasculitis Complicating Nivolumab Therapy for Hodgkin Lymphoma (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0531; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description A 40-year-old female with Hodgkin lymphoma treated with cyclophosphamide/vincristine, now on brentuximab-nivolumab, developed a diffuse rash...Nivolumab was discontinued, and corticosteroids and losartan were initiated...The challenge lies in attributing the IgA vasculitis to nivolumab versus the underlying malignancy, as lymphoma recurrence raises the possibility of paraneoplastic pathogenesis and improvement in proteinuria after SCT favors a paraneoplastic mechanism, although we are unable to rule out nivolumab involvement. This case highlights the importance of screening for proteinuria and hematuria in patients who are receiving ICIs and introduces the clinical dilemma when ICI discontinuation due to nephrotoxicity compromises oncologic outcomes."
Clinical • Fibrosis • Glomerulonephritis • Hematological Malignancies • Hodgkin Lymphoma • IgA Nephropathy • Immunology • Lupus Nephritis • Lymphoma • Nephrology • Renal Disease • Vasculitis
|
|
Shadi Memar; Yejin Andrea Kim; Toni Sabbouh
|